Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer

NCT00690300 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT00690300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00690300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2008
Completion date
December 31, 2010
Enrollment
44 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas neoplasms